Zymeworks to Acquire Theravance Biopharma for $929 Million: A Strategic Move Beyond Oncology
Canadian biotechnology company Zymeworks Inc. has announced the acquisition of Theravance Biopharma in a deal valued at approximately…
Canadian biotechnology company Zymeworks Inc. has announced the acquisition of Theravance Biopharma in a deal valued at approximately…